Tim A. Ahles, PhD, on Neurocognitive Late Effects
2016 Cancer Survivorship SymposiumTim A. Ahles, PhD, of Memorial Sloan Kettering Cancer Center, discusses “chemobrain” and what can be done to help patients cope with this symptom.
Tim A. Ahles, PhD, of Memorial Sloan Kettering Cancer Center, discusses “chemobrain” and what can be done to help patients cope with this symptom.
Craig E. Pollack, MD, of Johns Hopkins University, discusses a study of survivorship care plans for this special population (Abstract 1).
Mary McCabe, RN, of Memorial Sloan Kettering Cancer Center, discusses various models of delivering survivorship care.
Kevin C. Oeffinger, MD, of Memorial Sloan Kettering Cancer Center, summarizes the main take-home messages of the conference.
Smita Bhatia, MD, MPH, of the University of Alabama at Birmingham, discusses long-term and late effects experienced by cancer survivors.
Kerri M. Winters-Stone, PhD, of Oregon Health and Science University, discusses the results of her study, which showed that, years after treatment, nearly half of women cancer survivors still have symptoms of chemotherapy-induced peripheral neuropathy. The findings may inform rehabilitative programs to prevent falls and injuries (Abstract 130).